In our clinical work in recent years, we found some adolescents who visited us for very severe urinary frequency, urgency, painful urination, hematuria, difficult urination, and urge incontinence, but could not be explained and treated with common urological disease diagnosis and management ideas. After detailed history taking and analysis, it was found that they all possessed an insidious common feature: long-term use of the drug ketamine (ketamine). Our research team identified and reported this particular urinary impairment – ketamine associated urinary dysfunction (KAUD) – and this new disease, which emerged in a specific social context, gradually became clear to urologists and showed This new disease, which has emerged in a specific social context, is becoming clear to urologists and is showing an increasing trend. However, there are too many unknowns and questions behind it waiting for us to explore and discover. In 1978, Siegel first reported cases of ketamine abuse in San Francisco and Los Angeles, and ketamine became popular as a drug of abuse in Europe and the United States in the late 1980’s. Since 2001, ketamine has become the most abused drug in Hong Kong, and during the same period, it began to flow into the Mainland. With the continuous decline in price, the new drug abuse phenomenon represented by ketamine in China has increased sharply in recent years, and has the following characteristics: ① the prevalence of drug use is rising rapidly; ② the recreational drug use behavior is becoming more widespread among youth and adolescents; ③ the trend of low age of the abusing population, with adolescents as the main group, the lowest age is only 12 years old. The lowest age is only 12 years old. According to figures released by the National Drug Control Office and the Ministry of Public Security’s Drug Control Bureau on January 22, 2011, the number of “post-90s” drug users in the country rose from 17,000 in 2008 to 37,000 in 2009, an increase of 115% in one year, of which more than 60% were abusing ketamine. Although the state has not yet released the data for the past year, but we can clearly understand that these figures are only the tip of the iceberg. We believe that KAUD is a total urinary tract injury with lower urinary tract symptoms as the first clinical manifestation. Without any intervention and withdrawal, the disease process is: LUTS → bladder muscle and interstitial damage → bladder/ureteral fibrosis → obstructive nephropathy (and/or interstitial nephritis) → CKD → ESRD → death As a new disease emerging in a new social environment, ketamine-related urinary tract damage research has a strong social value. The number of hidden KAUD patients is large and this group is growing rapidly. Due to the addictive nature of the drug, most patients are simply unable to quit ketamine abuse and enter the irreversible process of lower urinary tract injury and renal impairment in a sequential manner, and when end-stage renal disease (ESRD) develops, they will have to receive lifelong renal replacement therapy. The heavy economic burden and long-term low quality of life of these patients, who are mostly in the youth population, will definitely lead to a great waste of public medical resources and a heavy burden of national medical investment, increasing social instability. KAUD was first reported in Canada and Hong Kong in 2007, and in 2008 we were the first to identify and report this particular urological disorder in mainland China, and conducted a series of studies, including: clinical features, diagnostic methods, imaging features, and epidemiological characteristics of the disease, and carried out basic research. The results of the study were referred to and adopted by the Ministry of Health and the Ministry of Public Security, providing a scientific and effective basis for national health decision-making and drug detection management. In 2001, the State Drug Supervision Bureau included ketamine in the management of Class II psychotropic substances, and in 2003, the Ministry of Public Security officially included ketamine in the category of drugs (Public Drug Control [2003] No. 481), and the State Ministry of Health (Health Planning Commission) officially released the disease diagnosis and treatment methods to the society in October 2012. A series of public health issues related to the development of disease codes and treatment methods for this disease are receiving widespread attention from scholars at home and abroad. The patient, male, 22 years old, had frequent and urgent urination 6 months ago, and his symptoms were progressively worsening. His diet was acceptable, his sleep was poor, and he had lost about 12 kg in the past 2 years. Physical examination: pressure pain in the suprapubic bladder area, but no clear positive signs. History: denied history of smuggling, trauma, allergy, and a history of long-term use of new drugs (ketamine) for 4 years, complained of withdrawal for 2 weeks. There was no family history of genetic disease or similar patients, and there were similar patients in the surrounding population. Recurrent severe pain in the suprapubic region and epigastric region. Previously treated for chronic prostatitis and urinary tract infection with poor results.